United Therapeutics Stock
Price
Target price
€408.60
€408.60
-0.270%
-1.1
-0.270%
€481.07
19.02.26 / Tradegate
WKN: 923818 / Symbol: UTHR / Name: Utd Therapeut / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
United Therapeutics Stock
United Therapeutics shows a slight decrease today, losing -€1.100 (-0.270%) compared to yesterday.
The stock is one of the favorites of our community with 24 Buy predictions and 1 Sell predictions.
As a result the target price of 481 € shows a slightly positive potential of 17.72% compared to the current price of 408.6 € for United Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for United Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of United Therapeutics in the next few years
Pros
?
B****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of United Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| United Therapeutics | -0.270% | 1.895% | 2.329% | 16.876% | -4.376% | 70.962% | 181.793% |
| Iovance Biotherapeutics Inc. | 1.220% | 12.889% | 17.326% | -54.209% | 3.204% | -64.989% | -93.712% |
| Neurocrine Bioscience | -1.900% | 4.400% | -4.922% | -1.266% | -10.569% | 12.933% | 16.688% |
| Ligand Pharmaceuticals | 1.240% | 0.637% | -0.629% | 37.391% | -4.819% | 131.536% | 33.785% |
Comments
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) was given a new $645.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for UTHR provided by MarketBeat
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at UBS Group AG from $580.00 to $600.00. They now have a "buy" rating on the stock.
Show more
Ratings data for UTHR provided by MarketBeat